ClinicalTrials.gg
CompletedNCT01143181Updated Aug 12, 2021Results posted

Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses

A Phase 3 interventional study of Brincidofovir in Double-stranded DNA Virus, sponsored by Chimerix. Completed at 37 sites in United States. Per ClinicalTrials.gov, last updated 2021-08-12.

Sponsored by Chimerix (part of Jazz Pharmaceuticals) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Adenoviridae Infections with a site in United States — 17 open to participants now, 21 under way, 2 of them phase 3. Adenoviridae Infections · United States.

Enrollment
9th of 68
210 · median 27
Started
2010
with 1 other
Phase 3
6 of 78
2 open now
Registered
20th of 78
by date
Lead sponsor
6 of 78
Chimerix

Among the 78 studies in Adenoviridae Infections with a site in United States, this one is the 9th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2010, is one of 6 in phase 3, and was the 20th registered.

Adenoviridae Infections

136 studies on the registry are indexed under Adenoviridae Infections; 34 are open to participants now.

Browse Adenoviridae Infections studies →

Open to participants now

17 of the 78 studies in Adenoviridae Infections with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Adenoviridae Infections studies recruiting now, 9 (36%) set no upper age limit and 12 (48%) stop at 75 or younger; 17 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Adenoviridae Infections with a site in United States, or all of them as a file.
02

Study summary

This was a multicenter, open-label study of oral brincidofovir (BCV) treatment of serious disease or conditions caused by double-stranded DNA (dsDNA) virus(es). Subjects received either a weight-based or a fixed dose of oral BCV once weekly (QW) or twice weekly (BIW) for up to 3 months until clinical disease was resolved or stabilized and/or viral DNA by polymerase chain reaction testing was negative for 4 consecutive weeks, whichever was longer. Under the first protocol amendment, adults and adolescents (≥13 years) received 200 mg or 300 mg BCV BIW (not to exceed 4 mg/kg total weekly dose) depending on the difficulty of treating their disease (i.e., Group 1 or Group 2, respectively), and pediatric subjects (≤12 years) received 4 mg/kg BCV BIW. Under the second protocol amendment, adults and adolescents (≥13 years), regardless of viral infection/disease, had a maximum weekly dose of 200 mg, i.e., 200 mg QW or 100 mg BIW; not to exceed 4mg/kg total weekly dose. Pediatric subjects (≤12 years), regardless of viral infection/disease, had a maximum weekly dose of 4 mg/kg, i.e., 4 mg/kg QW or 2 mg/kg BIW; not to exceed 200 mg.

Read the detailed description

This was a multicenter, open-label study of oral brincidofovir (BCV) treatment of serious disease or conditions caused by double-stranded DNA (dsDNA) virus(es).

Subjects with a life-threatening or serious disease or condition caused by infection with any dsDNA virus(es), who met the protocol eligibility criteria and who were approved by the Chimerix Medical Monitor were enrolled in this open-label treatment study. During the course of the study, the viral disease indications were narrowed in Amendment 2 to cytomegalovirus, adenovirus, herpes simplex virus, vaccinia virus, variola virus, or monkeypox virus to focus on indications that were under study in controlled clinical trials of oral BCV and on viral disease with few, if any, options for treatment. However, subjects with other viral disease indications may have been enrolled with the approval of the Chimerix Medical Monitor.

Subjects received either a weight-based or a fixed dose of oral BCV once weekly (QW) or twice weekly (BIW) for up to 3 months until clinical disease was resolved or stabilized and/or viral DNA by polymerase chain reaction testing was negative for 4 consecutive weeks, whichever was longer. Subjects who met criteria for resolution of viral disease may have: 1) discontinued BCV; 2) reduced the dose or dosing frequency of BCV; or 3) continued BCV QW or BIW, depending on the investigator's assessment of the risk of relapse and following discussion with the Chimerix medical monitor.

03

Conditions studied

  • Double-stranded DNA Virus

Keywords

  • Cytomegalovirus
  • Adenovirus
  • Herpes simplex virus
  • Vaccinia virus
  • Variola virus
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects were required to meet all of the following inclusion criteria in order to participate in the study:

  1. Had an immediately life-threatening or serious disease or condition caused by infection with a double-stranded DNA virus (including subjects with recurrent viral disease). [Note: During the course of the study, the viral disease indications were narrow to focus on indications that were under study in controlled clinical trials of brincidofovir (BCV) and on viral diseases that had few, if any, options for treatment, including cytomegalovirus (CMV), adenovirus (AdV), herpes simplex virus (HSV), vaccinia virus (VAVC), variola virus (VARV) or monkeypox viruses(s).]
  2. Had a of at least 2 weeks and commitment to continuation of supportive care for at least 4 weeks.
  3. Were able to ingest and absorb oral medication (in the judgment of the investigator and based on lack of significant gastrointestinal [GI] pathology such as small bowel resection or ileus). [Note: Use of total parenteral nutrition was not in and of itself exclusionary as long as the reason for use did not disqualify the subject based on this criterion.]
  4. Were willing and able to understand and provide written . [Note: For minors or those incapable of providing written informed consent (i.e., incapacitated), consent was provided by a parent or legal guardian or representative who could understand and provide written informed consent.]
  5. Were willing and able, to the best of his or her (or parent/guardian) knowledge, to participate in all required study activities for the duration of the study.
  6. If female of , agreed to use 2 acceptable methods of throughout the study with at least 1 being a barrier method.
  7. In the judgment of the investigator, subjects for whom no comparable or satisfactory therapeutic alternative was available

Exclusion criteria

Exclusion Criteria

Subjects were not to be enrolled if they met any of the following exclusion criteria:

  1. Were pregnant or currently nursing.
  2. Had to cidofovir or BCV.
  3. Had a long-term prognosis that included a poor likelihood of survival due to irreversible organ failure including, for example, subjects with frank hepatic failure and adults with Grade 4 of the GI tract.
  4. Were eligible for enrollment and able to participate in a clinical trial evaluating BCV. [Note: Per the FDA guidance, subjects eligible and able to participate in a controlled clinical study evaluating BCV were not eligible for participation in this study. Subjects who did not meet eligibility criteria for a controlled BCV clinical study or who were unable to participate because, for example, of logistical or other issues were eligible to participate in this study. The investigator verified that his/her subjects met this criterion on the Eligibility electronic case report form. A subject simply preferring enrollment in this study over a BCV controlled clinical trial did not qualify for enrollment in this study.]
  5. Had any other condition that would have, in the judgment of the investigator, put the subject at increased risk during participation in the study or interfered with the conduct of the study.
  6. Had a serum total value >5 x the reference range, taking into account the age and/or gender of the subject. [Note: In order to avoid any unwarranted delay to the start of BCV treatment, compliance with this exclusion criterion may have been determined based on the results of testing performed at a local safety laboratory, rather than waiting for results from the designated central safety laboratory. If relying on local safety laboratory test results, the blood sample must have been collected no more than 7 days prior to the scheduled first dose administration on Day 0, otherwise it was repeated. A subject whose elevated bilirubin was due to the underlying viral disease may still have been enrolled into the study if the participation of the subject was prospectively approved by the Chimerix Medical Monitor.]

Subjects with acute or chronic renal impairment, pediatric and adolescent subjects, and subjects aged 65 years and older were included in this study. Subjects with hepatic impairment were included unless the investigator judged that the subject had irreversible hepatic compromise.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Brincidofovir

    Subjects received either a weight-based or a fixed-dose of oral brincidofovir (BCV) once weekly or twice weekly for up to 3 months until clinical disease was resolved or stabilized and/or viral DNA polymerase chain reaction testing was negative for 4 consecutive weeks, whichever was longer.

    Drug: Brincidofovir

Interventions

  • Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.

    Also known as: CMX001, BCV

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Had a Sustained and Significant Reduction in Plasma Viral Load of Primary dsDNA Virus

    Proportion of subjects who achieved a confirmed reduction in viral load for the primary dsDNA virus of ≥1 log10 copies/mL from baseline or to an undetectable level. Confirmation required the reduction in viral load (i.e., decrease of ≥ 1 log10 copies/mL from baseline or to undetectable levels) to be maintained at the next assessment for the subject to be considered a success.

    Time frame: 3 months

07

Results

Posted Aug 12, 2021

Participant flow

This was an expanded access study with the primary objective of providing brincidofovir (BCV) to subjects with serious or life-threatening conditions caused by double-stranded DNA viral infections. All subjects enrolled received BCV for up to 3 months until their clinical disease was resolved or stabilized and/or viral DNA testing was negative for 4 consecutive weeks, whichever was longer.

Participant flow — Overall Study
MilestoneBCV (≤4 mg/kg/Week)BCV (>4 mg/kg/Week)BCV (≤200 mg/Week)BCV (>200 mg/Week)
Started303810240
Completed14225817
Not completed16164423

Outcome measures

PrimaryNumber of Subjects Who Had a Sustained and Significant Reduction in Plasma Viral Load of Primary dsDNA Virus

Proportion of subjects who achieved a confirmed reduction in viral load for the primary dsDNA virus of ≥1 log10 copies/mL from baseline or to an undetectable level. Confirmation required the reduction in viral load (i.e., decrease of ≥ 1 log10 copies/mL from baseline or to undetectable levels) to be maintained at the next assessment for the subject to be considered a success.

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Subjects Who Had a Sustained and Significant Reduction in Plasma Viral Load of Primary dsDNA Virus
ParticipantsBCV (≤4 mg/kg/Week)BCV (>4 mg/kg/Week)BCV (≤200 mg/Week)BCV (>200 mg/Week)
Number of Subjects Who Had a Sustained and Significant Reduction in Plasma Viral Load of Primary dsDNA Virus15183913

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCV (≤4 mg/kg/Week)—27/30 (90%)30/30 (100%)
BCV (>4 mg/kg/Week)—32/38 (84.2%)37/38 (97.4%)
BCV (≤200 mg/Week)—80/102 (78.4%)101/102 (99%)
BCV (>200 mg/Week)—35/40 (87.5%)40/40 (100%)
Most frequent serious events
Showing 10 of 223
Most frequent serious events
EventBCV (≤4 mg/kg/Week)BCV (>4 mg/kg/Week)BCV (≤200 mg/Week)BCV (>200 mg/Week)
Respiratory failureRespiratory, thoracic and mediastinal disorders6/305/389/1024/40
Acute graft versus host diseaseImmune system disorders0/302/3813/1027/40
DiarrhoeaGastrointestinal disorders2/303/3817/1026/40
PyrexiaGeneral disorders5/306/3811/1020/40
Multi-organ failureGeneral disorders3/301/387/1026/40
HypotensionVascular disorders1/304/387/1020/40
Abdominal painGastrointestinal disorders3/301/384/1021/40
Lower gastrointestinal haemorrhageGastrointestinal disorders3/301/380/1020/40
NauseaGastrointestinal disorders0/301/389/1024/40
VomitingGastrointestinal disorders2/302/387/1024/40
Most frequent other events
Showing 10 of 128
Most frequent other events
EventBCV (≤4 mg/kg/Week)BCV (>4 mg/kg/Week)BCV (≤200 mg/Week)BCV (>200 mg/Week)
DiarrhoeaGastrointestinal disorders12/3022/3861/10219/40
PyrexiaGeneral disorders13/309/3825/1024/40
NauseaGastrointestinal disorders3/306/3842/1029/40
VomitingGastrointestinal disorders8/3013/3830/1027/40
Acute graft versus host diseaseImmune system disorders8/3011/3830/10211/40
HypertensionVascular disorders8/303/387/1024/40
Abdominal painGastrointestinal disorders6/307/3826/1024/40
HypokalaemiaMetabolism and nutrition disorders7/304/389/1022/40
Respiratory failureRespiratory, thoracic and mediastinal disorders7/305/3810/1026/40
NeutropeniaBlood and lymphatic system disorders3/302/3816/1028/40

Baseline characteristics

This was an expanded access study with the primary objective of providing brincidofovir (BCV) to subjects with serious or life-threatening conditions caused by double-stranded DNA viral infections. All subjects enrolled received BCV for up to 3 months until their clinical disease was resolved or stabilized and/or viral DNA testing was negative for 4 consecutive weeks, whichever was longer.

Age, Continuous
Age, Continuous(years)BCV (≤4 mg/kg/Week)BCV (>4 mg/kg/Week)BCV (≤200 mg/Week)BCV (>200 mg/Week)Total
Mean5.2 ± 2.685.9 ± 3.7045.3 ± 17.2145.7 ± 17.5732.5 ± 23.51
Sex: Female, Male
Sex: Female, Male(Participants)BCV (≤4 mg/kg/Week)BCV (>4 mg/kg/Week)BCV (≤200 mg/Week)BCV (>200 mg/Week)Total
Female1414411887
Male16246122123
08

Study locations

37 sites
  • Loma Linda University Hospital
    Loma Linda, California 92354, United States
  • Children's Hospital of LA
    Los Angeles, California 90027, United States
  • UCLA Department of Medicine
    Los Angeles, California 90095, United States
  • CHOC Children's
    Orange, California 92868, United States
  • Univeristy of San Francisco
    San Francisco, California 94143, United States
  • Lucile Packard Children's Hospital
    Stanford, California 94304, United States
  • Children's Hospital of Colorado
    Aurora, Colorado 80045, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Childrens Hospital LSU
    New Orleans, Louisiana 70118, United States
  • NIH
    Bethesda, Maryland 20892, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Brigham and Womens Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • St. Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-5130, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Mt. Sinai
    New York, New York 10029, United States
  • Columbia University
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Institute
    New York, New York 10065, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Levine Children's Hospital Carolina Medical Center
    Charlotte, North Carolina 28203, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cincinnati Childrens Hospital
    Cincinnati, Ohio 45229, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Childrens Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104-2796, United States
  • UT MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Intermountain BMT program LDS Hospital
    Salt Lake City, Utah 84143, United States
  • University of Washington-Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Tippin TK, Morrison ME, Brundage TM, Mommeja-Marin H. Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies. Ther Drug Monit. 2016 Dec;38(6):777-786. doi: 10.1097/FTD.0000000000000353. PubMed 27851688 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2010 to primary completion in Dec 2012, 24 months.

Results were first posted in Aug 2021, 8 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2010
First posted
Jun 14, 2010
StartActual
Dec 2010
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Aug 12, 2021
Last update
Aug 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01143181
Lead sponsor
Chimerix
Responsible party
Sponsor
First posted
Jun 14, 2010
Start date
Dec 2010
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Aug 12, 2021
Last update
Aug 12, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brincidofovir

Start the discussion